Subscribe
ftc-istock-530746621-rivernorthphotography
RiverNorthPhotography / iStockphoto.com
29 March 2017Americas

FTC hails M&A activity in ‘historic’ 2016

Last year was a historic one for the US Federal Trade Commission, according to its “ Annual Highlights” report, issued yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.
Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More features

Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case